NCT01945762 - Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 17, 2014

Primary Completion Date

June 18, 2020

Study Completion Date

June 18, 2020

Conditions

Symptomatic, Aggressive, Sporadic, Unresectable, LocallyAdvanced/Metastatic Medullary Thyroid Cancer (MTC)

Interventions

DRUG

Vandetanib 300 mg

Vandetanib commercial tablets

Trial Locations (8)

investigational Site Belgium, Belgium

investigational Site France, France

investigational Site Germany, Germany

investigational Site Italy, Italy

investigational Site Luxembourg, Luxembourg

investigational Site Netherlands, Netherlands

investigational Site Spain, Spain

investigational Site United Kingdom, United Kingdom